天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook >> journal list >> European journal of pharmacology >>article
European journal of pharmacology

European journal of pharmacology

IF: 4.2
Download PDF

Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic

Published:5 March 2021 DOI: 10.1016/j.ejphar.2021.173854 PMID: 33428898
Sobia Noreen, Irsah Maqbool, Asadullah Madni

Abstract

The current outbreak of novel COVID-19 challenges the development of an efficient treatment plan as soon as possible. Several promising treatment options stand out as potential therapy of COVID-19, including plasma-derived drugs, monoclonal antibodies, antivirals, antimalarial, cell therapy, and corticosteroids. Dexamethasone an approved corticosteroid medication, acting as an anti-inflammatory and immunosuppressant agent. In the current pandemic, dexamethasone is declared a “major development” in the fight against COVID-19. Steroidal dexamethasone was presented as the recent advancement that significantly reduces the mortality rate among severe COVID-19 cases. This review summarizes the preliminary opinion about the dexamethasone outbreak, therapeutic potential, risks, and strategies during the COVID-19 pandemic.

Substances (1)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Dexamethasone 50-02-2 C22H29FO5 783 suppliers $20.00-$5210.50

Similar articles

IF:4.2

Salmon calcitonin: a review of current and future therapeutic indications.

Osteoporosis International C H Chesnut, M Azria,etc Published: 1 April 2008
IF:4.7

Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19.

Infectious Diseases and Therapy Takahiro Takazono,?Satoki Fujita,etc Published: 1 August 2024
IF:7.6

Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial

The Lancet Regional Health: Western Pacific Fuxiang Wang , Wen Xiao ,etc Published: 1 September 2023